Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.  
Home Contact us sitemap
  News releases
Tianyuan's Meningococcal Polysaccharide Vaccine Exported to Indonesia
Publisherty-pharm Date:2009-2-11 Font: Big Medium Small

Tianyuan's Group ACYW135 Meningococcal Polysaccharide vaccine has been exported to Indonesia in January of 2009 following successful governmental bid-winning. This is the fisrt time to export the Meningococcal Polysaccharide vaccine, which means Tianyuan has moved the fisrt step on overseas market for "YUNAONING"


Meningococcal Polysaccharide Vaccine

Meningococcal meningitis caused by the bacterium Neisseria meningitides, is a serious infection of the fluid in the spinal cord and the fluid that surrounds the brain and can result in brain damage and even death.

The bacteria are spread by direct close contact with the discharges from the nose or throat of an infected person.

Meningococcal meningitis is most common in infants and children. People who have had close or prolonged contact with a patient with meningococcal meningitis are at increased risk.

Bacterial meningitis can be treated with antibiotics, but an early diagnosis and treatment is crucial.

To prevent the disease, vaccines are the best choice.

Tianyuan produces 3 types of polysaccharide meningitis vaccines: one mono-valent: Men A, one di-valent: Men AC, and one tetra-valent: Men ACYW135 which are filled into vials and lyophilized in freeze-dryers. Tianyuan also provides the reconstitution solution. This process allows an excellent shelf-life of the product. Finally, the vaccine quality is checked and then marketed after approval by the national regulatory authority (SFDA).

Tianyuan aspires to get the WHO-prequalification for its vaccines.

Print || Close Windows
Copyright(C)2008,Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. All Rights Reserved.
 Supported by  ChinaPharmNet Toocle